Compare RNW & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNW | VERA |
|---|---|---|
| Founded | 2011 | 2016 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 1.5B |
| IPO Year | N/A | 2021 |
| Metric | RNW | VERA |
|---|---|---|
| Price | $5.54 | $55.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $7.25 | ★ $76.60 |
| AVG Volume (30 Days) | ★ 2.0M | 1.9M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 413.66 | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,382,164,625.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $20.72 | ★ N/A |
| Revenue Growth | ★ 46.76 | N/A |
| 52 Week Low | $5.05 | $18.53 |
| 52 Week High | $8.24 | $55.00 |
| Indicator | RNW | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 24.76 | 82.73 |
| Support Level | $5.05 | $47.22 |
| Resistance Level | $5.69 | $51.19 |
| Average True Range (ATR) | 0.19 | 2.94 |
| MACD | -0.16 | 0.63 |
| Stochastic Oscillator | 19.30 | 97.57 |
ReNew Energy Global PLC is a developer and operator of clean energy projects intended to meet India's growing energy needs in an efficient, sustainable and socially responsible manner. The company provides end-to-end solutions in a just and inclusive manner in the areas of clean energy, value-added energy offerings through digitalization, storage, and carbon markets that increasingly are integral to addressing climate change. The company has four reportable segments: wind power and solar power, hydro power and transmission line. It derives maximum revenue from Wind Power segment.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.